Total Funding
50
39
Total FundingPost-IPO Debt raised
Growth Score
16 pts
Heat Score
-20 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
30045
Sarepta Therapeutics focuses on the discovery and development of precision genetic medicine to treat rare diseases.
- Douglas Ingram: CEO and PresidentPast Role: Chase Pharmaceuticals, Chief Executive Officer
Alex Lagadinos: Associate Director, Corporate DevelopmentPast Role: Sarepta Therapeutics, Senior Manager, Business Development
About the Company
Sarepta Therapeutics is a biopharmaceutical company that focuses on the discovery and development of precision genetic medicine to treat rare diseases. It specializes in gene therapy, RNA-targeted exon skipping, and gene editing.
It was founded in 1980 and headquartered in Cambridge, Massachusetts.
